Stock QBIO Q BIOMED INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Q BioMed Inc.

Equities

QBIO

US74736N1054

Market Closed - OTC Markets
Other stock markets
 02:32:26 2024-04-18 pm EDT 		5-day change 1st Jan Change
0.0002 USD +100.00% Intraday chart for Q BioMed Inc. 0.00% -50.00%
2023 Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023 CI
2023 Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2022 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Q BioMed Inc. Provides Update to Shareholders
PR
Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023
CI
Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2022
CI
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe
AQ
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe
PR
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office
AQ
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office
PR
Q BioMed Inc.'s Chemotherapeutic Uttroside B Receives Notice of Allowance for Patent from United States Patent Office
CI
Q BIOMED INC. : Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)
AQ
Q BioMed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022
CI
Q BIOMED PROVIDES SHAREHOLDER UPDATE
PR
Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER
PR
Q BioMed Inc. Announces Issuance of Patent for Groundbreaking Gdf15 Biomarker
CI
Q BioMed Inc. Provides Update to Shareholders
PR
Q BioMed Inc. Reports Second Quarter Revenues in 2022
CI
Q BioMed : Quarterly Report for Quarter Ending May 31, 2022 (Form 10-Q)
PU
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)
AQ
Q BioMed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022
CI
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. QBIO Stock
  4. News Q BioMed Inc.